Abstract
Aim:In this prospective case–control study we aimed to compare diagnostic value of plasma PARK7 and NDKA in early diagnosis of acute stroke and evaluate the validated diagnostic values of PARK7 and NDKA in an independent patient cohort. We then assessed the quantitative relationship between the release of these markers: stroke severity and time. Blood samples were drawn upon hospital admission and 14 days later. PARK7 and NDKA concentrations were measured using an ELISA.Results:The expression of PARK7 (area under the curve [AUC] = 0.897) in acute stroke patients was more significant than in controls, relative to the NDKA expression (AUC = 0.462); p < 0.05. Their expressions were not related to the clinical characteristics of both groups; p > 0.05.Conclusion:Even though both markers cannot differentiate stroke etiologies (ischemic or hemorrhagic), plasma PARK7 has better diagnostic value than NDKA for early diagnosis of stroke. 72 plasma samples obtained from acute stroke patients and 78 plasma samples collected from non-stroke patients were analyzed in this study.
Highlights
ObjectivesIn this prospective case–control study we aimed to compare diagnostic value of plasma PARK7 and NDKA in early diagnosis of acute stroke and evaluate the validated diagnostic values of PARK7 and NDKA in an independent patient cohort
The results demonstrated that both molecules can identify patients with the three types of stroke, there was no statistical difference in the capacity of PARK7 and NDKA to identify ischemic stroke (IS), hemorrhagic stroke (HS) or subarachnoid hemorrhage (SAH) (p > 0.0166)
Conclusion the ultimate purpose of this study was to elucidate which biomarker of PARK7 and NDKA is more reliable for diagnosis of acute stroke, we recognize its limitation: small size of sample
Summary
In this prospective case–control study we aimed to compare diagnostic value of plasma PARK7 and NDKA in early diagnosis of acute stroke and evaluate the validated diagnostic values of PARK7 and NDKA in an independent patient cohort. The aim of this study was to determine which one has more diagnostic value for acute stroke. The aim of our study was to compare the diagnostic value of plasma PARK7 and NDKA. Conclusion the ultimate purpose of this study was to elucidate which biomarker of PARK7 and NDKA is more reliable for diagnosis of acute stroke, we recognize its limitation: small size of sample. PARK7 and NDKA have been identified as playing role in stroke pathophysiology and as biomarkers for early diagnosis of stroke. Our aim was to compare the diagnostic value of PARK7 and NDKA in acute stroke.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
